RA0058

antibody from Oursmab

Targeting: CA9 CAIX, MN

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0058

Provider

Oursmab

Product name

Girentuximab (Biosimilar Reference Antibody) (CA9)

Antibody type

Monoclonal

Description

Girentuximab (development code cG250) is an investigational, chimeric monoclonal IgG1 antibody developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC). It functions as a targeted agent against a specific carbonic anhydrase isoform. Girentuximab binds with high affinity to its target antigen, which is highly expressed on the surface of ccRCC cells. For therapeutic purposes, it has been investigated in radiolabeled forms (e.g., with lutetium-177 or iodine-131) as a radioimmunotherapy (RIT), delivering localized radiation directly to the tumor. It has also been studied as an unlabeled ("naked") antibody to engage immune effector mechanisms like antibody-dependent cellular cytotoxicity (ADCC).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.